Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic-Genetic Crosstalk at the Cancer-Diabetes Interface: Convergent Molecular Pathways, Multi-Omics Biomarkers, and Dual Therapeutic Targets.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Design and Development of a Novel LXRβ/PPARδ Dual Agonist for Memory Impairment and Pathology in 3xTg-AD Animal Model of Alzheimer's Disease.

ACS chemical biology·2026
Same author

Protein Kinase C-Delta (PKCδ) inhibition stabilizes endothelium and suppresses triple-negative breast cancer (TNBC) intravasation in a microfluidic hypoxic tumor model.

Bioengineering & translational medicine·2026
Same author

The Pivotal Role of HDAC6 in Amyotrophic Lateral Sclerosis: Neuroprotective Protagonist or Degenerative Adversary?

Current neuropharmacology·2026
Same author

Investigating the Anticancer Promise of Synthesized Methylated N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides: Biological and Computational Characterization.

Chemical biology & drug design·2026
Same author

Vacuolization as a Novel Approach to Cancer Therapy.

Journal of biochemical and molecular toxicology·2026

Related Experiment Video

Updated: Aug 26, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Gefitinib Inhibits Rifampicin-Induced CYP3A4 Gene Expression in Human Hepatocytes.

Kodye L Abbott1,2,3, Julia M Salamat1,2, Patrick C Flannery1,2,3

  • 1Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, Alabama 36849, United States.

ACS Omega
|October 3, 2022
PubMed
Summary
This summary is machine-generated.

Gefitinib (GEF) may counteract chemoresistance by blocking the human pregnane xenobiotic receptor (hPXR) and its target gene CYP3A4. This finding suggests GEF as a potential adjunct therapy to combat drug resistance in cancer treatment.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Experiment Videos

Last Updated: Aug 26, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Activation of the human pregnane xenobiotic receptor (hPXR) contributes to chemoresistance during combination chemotherapy.
  • hPXR activation leads to the upregulation of target genes like CYP3A4, a drug metabolism enzyme, exacerbating drug resistance.
  • There is a clinical need for hPXR antagonists to be used alongside chemotherapy.

Purpose of the Study:

  • To investigate if Gefitinib (GEF), a tyrosine kinase inhibitor, acts as an hPXR antagonist.
  • To determine GEF's efficacy in inhibiting hPXR agonist-induced CYP3A4 expression.
  • To explore GEF's potential as an adjunct therapy against hPXR-mediated chemoresistance.

Main Methods:

  • Utilized therapeutic concentrations of GEF and rifampicin (RIF), a known hPXR agonist.
  • Assessed GEF's effect on RIF-induced CYP3A4 gene expression in human primary hepatocytes and hepatocells.
  • Evaluated GEF's impact on RIF-induced hPXR-mediated CYP3A4 promoter activity in HepG2 cells.
  • Employed computational molecular docking and cell-free assays to analyze GEF-hPXR interactions.

Main Results:

  • GEF significantly inhibited RIF-induced upregulation of endogenous CYP3A4 gene expression in human hepatocytes.
  • GEF suppressed RIF-induced hPXR-mediated CYP3A4 promoter activity in HepG2 cells.
  • Molecular docking and cell-free assays confirmed GEF directly binds to the hPXR ligand-binding domain.

Conclusions:

  • Gefitinib antagonizes hPXR agonist-induced CYP3A4 gene expression at clinically relevant concentrations.
  • GEF demonstrates potential as a therapeutic agent to overcome hPXR-mediated chemoresistance.
  • Further research is needed to confirm GEF's effectiveness in combating hPXR agonist-induced chemoresistance in clinical settings.